ArticleFrontiers in oncology2025
Borderline ovarian clear cell tumor arising from endometriosis during long-term dienogest therapy: a case report.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometriomas, commonly known as ovarian chocolate cysts, are a prevalent condition in women of reproductive age. They are cysts formed by the ectopic growth of endometrial tissue within the ovary, often leading to dysmenorrhea and infertility. Dienogest is a first-line medication for the long-term management of endometriomas, control of associated pain, and prevention of postoperative recurrence. A 34-year-old woman presented to our hospital with dysmenorrhea and was diagnosed with an endometrioma. She subsequently commenced dienogest treatment for a total duration of thirty-two months. During this period, the cyst gradually decreased in size and eventually became undetectable. However, a follow-up ultrasound indicated the recurrence of the endometrioma after twenty-seven months. Five months later, a subsequent ultrasound revealed papillary growth with internal blood flow within the ovarian endometrioma. The patient underwent immediate surgical intervention. The postoperative pathology indicated a borderline clear cell tumor. Consequently, the patient promptly underwent comprehensive staging surgery, with the final pathology confirming no residual tumor. This case demonstrates that despite long-term and effective dienogest treatment, endometriomas retain the potential for malignant transformation. Therefore, regular monitoring during treatment and prompt intervention upon suspicion of malignancy are indispensable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.